TY - JOUR
T1 - Diagnostic accuracy of endoscopic ultrasonography-guided tissue acquisition prior to resection of pancreatic carcinoma
T2 - a nationwide analysis
AU - Quispel, Rutger
AU - Schutz, Hannah M.
AU - Keultjes, Augustinus W.P.
AU - Erler, Nicole S.
AU - Janssen, Quisette P.
AU - van Hooft, Jeanin E.
AU - Venneman, Niels G.
AU - Honkoop, Pieter
AU - Hol, Lieke
AU - Scheffer, Robert C.
AU - Bisseling, Tanya M.
AU - Voermans, Rogier P.
AU - Vleggaar, Frank P.
AU - Schwartz, Matthijs P.
AU - Verdonk, Robert C.
AU - Hoge, Chantal V.
AU - Kuiken, Sjoerd D.
AU - Curvers, Wouter L.
AU - van Vilsteren, Frederike G.I.
AU - Poen, Alexander C.
AU - Spanier, Marcel B.
AU - Bruggink, Annette H.
AU - Smedts, Frank M.
AU - van Velthuysen, Marie Louise F.
AU - van Eijck, Casper H.
AU - Besselink, Marc G.
AU - Veldt, Bart J.
AU - Koerkamp, Bas G.
AU - van Driel, Lydi M.J.W.
AU - Bruno, Marco J.
AU - Dutch Pancreatic Cancer Group (DPCG) and QUality in EndoSonography Team (QUEST)
N1 - Funding Information:
This work was supported by grants from Reinier de Graaf Gasthuis Scientific Committee , Team Westland, and the Dutch Gastroenterology Society (NVGE) .
Publisher Copyright:
© 2023 The Authors
PY - 2023/11
Y1 - 2023/11
N2 - Introduction: Endoscopic ultrasonography guided tissue acquisition (EUS + TA) is used to provide a tissue diagnosis in patients with suspected pancreatic cancer. Key performance indicators (KPI) for these procedures are rate of adequate sample (RAS) and sensitivity for malignancy (SFM). Aim: assess practice variation regarding KPI of EUS + TA prior to resection of pancreatic carcinoma in the Netherlands. Patients and methods: Results of all EUS + TA prior to resection of pancreatic carcinoma from 2014–2018, were extracted from the national Dutch Pathology Registry (PALGA). Pathology reports were classified as: insufficient for analysis (b1), benign (b2), atypia (b3), neoplastic other (b4), suspected malignant (b5), and malignant (b6). RAS was defined as the proportion of EUS procedures yielding specimen sufficient for analysis. SFM was calculated using a strict definition (malignant only, SFM-b6), and a broader definition (SFM-b5+6). Results: 691 out of 1638 resected patients (42%) underwent preoperative EUS + TA. RAS was 95% (range 89–100%), SFM-b6 was 44% (20–77%), and SFM-b5+6 was 65% (53–90%). All centers met the performance target RAS>85%. Only 9 out of 17 met the performance target SFM-b5+6 > 85%. Conclusion: This nationwide study detected significant practice variation regarding KPI of EUS + TA procedures prior to surgical resection of pancreatic carcinoma. Therefore, quality improvement of EUS + TA is indicated.
AB - Introduction: Endoscopic ultrasonography guided tissue acquisition (EUS + TA) is used to provide a tissue diagnosis in patients with suspected pancreatic cancer. Key performance indicators (KPI) for these procedures are rate of adequate sample (RAS) and sensitivity for malignancy (SFM). Aim: assess practice variation regarding KPI of EUS + TA prior to resection of pancreatic carcinoma in the Netherlands. Patients and methods: Results of all EUS + TA prior to resection of pancreatic carcinoma from 2014–2018, were extracted from the national Dutch Pathology Registry (PALGA). Pathology reports were classified as: insufficient for analysis (b1), benign (b2), atypia (b3), neoplastic other (b4), suspected malignant (b5), and malignant (b6). RAS was defined as the proportion of EUS procedures yielding specimen sufficient for analysis. SFM was calculated using a strict definition (malignant only, SFM-b6), and a broader definition (SFM-b5+6). Results: 691 out of 1638 resected patients (42%) underwent preoperative EUS + TA. RAS was 95% (range 89–100%), SFM-b6 was 44% (20–77%), and SFM-b5+6 was 65% (53–90%). All centers met the performance target RAS>85%. Only 9 out of 17 met the performance target SFM-b5+6 > 85%. Conclusion: This nationwide study detected significant practice variation regarding KPI of EUS + TA procedures prior to surgical resection of pancreatic carcinoma. Therefore, quality improvement of EUS + TA is indicated.
U2 - 10.1016/j.hpb.2023.07.900
DO - 10.1016/j.hpb.2023.07.900
M3 - Article
C2 - 37550169
SN - 1365-182X
VL - 25
SP - 1438
EP - 1445
JO - HPB
JF - HPB
IS - 11
ER -